Does Eli Lilly should trade at a premium to Novo Nordisk shares? For Deutsche Bank analyst James Shin, the reply is: “yes, but to not this degree.” Shin initiated coverage of a bunch of pharmaceutical stocks, including Eli Lilly, on Wednesday. The analyst said he’s frightened Lilly’s valuation is “grating against fundamentals,” as he set a price goal of $535 for the stock and gave it a hold rating. Lilly shares have soared nearly 62% for the reason that start of the 12 months as excitement has built over the potential of its portfolio, which incorporates an Alzheimer’s drug and tirzepatide, higher often known as Mounjaro for Type 2 diabetes and — as of Wednesday — Zepbound for obesity . “The GLP-1 phenomenon has lifted LLY’s FY24E EPS multiple to 48x – near all-time highs, leaving little room for upside,” Shin wrote in a research note. “LLY can also be trading at a 16x premium vs NVO… which looks stretched to us.” Shin’s price goal implies the shares will fall about 9% from where they closed Thursday. And it goes against the consensus on Wall Street, where the common price goal is about $626.17 per share, with a Street high of $722 per share. LLY YTD mountain Eli Lilly shares for the reason that start of the 12 months. In response to Shin, Lilly deserves a premium to Novo Nordisk because its portfolio is more diverse and it has less exposure to insulin. But, he said, these advantages are offset by Lilly’s exposure to the Inflation Reduction Act, which could pressure drug prices within the U.S. “We’re also early within the commercialization of GLP-1 for diabesity, which looming competitors could disrupt,” he said. “Yr-end market dynamics must even be considered for LLY’s near-term share outlook as funds might have to appreciate LLY’s premium to offset Biotech/Pharma sector weakness.” An infinite market The potential marketplace for anti-obesity medications is big, with greater than 40% of American adults having the condition, in keeping with the Centers for Disease Control and Prevention . Obesity is chronic, which implies patients might want to take the drugs long run or risk regaining weight. Many industry analysts see the market peaking at greater than $100 billion in annual sales by 2030 . Some have presented even richer forecasts. Novo Nordisk and Eli Lilly are far ahead of their rivals. Their drugs suppress the appetite and regulate insulin levels within the bloodstream by mimicking gut hormones. For Novo Nordisk ‘s Ozempic (Type 2 diabetes) and Wegovy (obesity) the goal is the hormone glucagon-like peptide-1. Lilly’s Mounjaro and Zepbound also key in on GLP-1. Nevertheless, the drug also imitates gastric inhibitory peptide, or GIP, which assists in breaking down sugar and fat as well. In clinical trials, patients on Wegovy lost about 15% of their weight, while those taking Zepbound lost about 21%. NVO YTD mountain Novo Nordisk shares 12 months up to now In the approaching weeks, Lilly will start rolling out Zepbound to patients. The drug will likely be costly, at an inventory price of $1,056 per 30 days, however it’s around 20% below Wegovy’s list price. As was the case with Wegovy, Lilly may have a savings card program that might reduce the fee of the drug for patients with business medical health insurance to as little as $25 per 30 days. Medicare cannot cover weight reduction medications. “While the web price for Zepbound could start above that of Mounjaro, we expect net price for each products to say no over time and to ultimately be in similar ranges over time,” wrote JPMorgan analyst Chris Schott in a research note. Supply constraints persist Insurance access to the drug is one hurdle for patients, but manufacturing also has been a key limiting factor. Each drugs have had periodic shortages. For the reason that spring, Novo Nordisk has been limiting access to low doses of Wegovy in a bid to guard supplies for patients already on the drug. Also, each firms have been ramping up manufacturing capability, but Novo recently said it can take years before it might probably produce enough Wegovy. “Given the worldwide magnitude of the chance, without knowing competitor supply capacities, then I do imagine it can be plenty of years, several years, before this market is unconstrained on a world basis,” Karsten Munk Knudsen, Novo’s chief financial officer, said on a recent earnings call. On Friday, Novo said it could invest greater than $6 billion to expand a plant in Denmark that makes Wegovy and other products. During Lilly’s recent earnings call, the corporate said it was heading in the right direction to double its production of its incretins, which also include one other diabetes drug, Trulicity. Schott said he expects each Novo and Lilly will sell nearly all of the product they can generate over the subsequent several years. Competition is coming And that is whilst other firms look to enter the segment. On Thursday, AstraZeneca signed a licensing agreement with Eccogene to develop an oral GLP-1 drug Lilly and Novo are each working on oral anti-obesity drugs . Lilly CEO David Ricks told CNBC on Thursday that the corporate has six other molecules in development . Schott expects Lilly shares to understand as more is learned in regards to the advantages of those drugs for other related conditions comparable to heart and kidney disease. He has an chubby rating on the stock. One such catalyst looms ahead on Saturday. Novo Nordisk is scheduled to release the total results of its Select cardiovascular trial on the American Heart Association conference. The corporate previously said the trial showed that patients taking Wegovy reported 20% fewer major cardiac events compared with patients not taking the drug. While the initial headline results were positive, analysts have been wanting to see greater detail from the study. Other studies are also within the works for sleep apnea and heart failure, with data expected in the primary half of 2024, Schott said. These trials have been seen as critical to gaining medical health insurance coverage and expanding use cases for the drugs. These studies also will help higher understand these drugs, that are still unknown over the long haul. There are some concerns about how long patients will resolve to remain on these medicines because of unwanted side effects comparable to gastrointestinal symptoms. — CNBC’s Michael Bloom contributed to this report.
Jim Cramer knocks down a recent analyst sell rating on a medtech stock as shortsighted
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a...
